Abstract

Johnson & Johnson is tapping Arrowhead Pharmaceuticals to license its experimental RNA interference (RNAi) therapy for the hepatitis B virus. Arrowhead will receive a $75 million equity investment and $175 million up front from J&J, and depending on how the RNAi therapy performs—currently in a Phase I/II study—Arrowhead could earn up to $1.6 billion in milestone payments. Finally, J&J may work with Arrowhead to develop three more RNAi therapies against additional targets, with $1.9 billion in potential milestone payments.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call